Challenges in RVO Care
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
Please CLICK HERE (https://www.eye-connect.org/rvo/1403-1/) to review the CME information and complete the pretest for this activity.
Join host Dr Sridhar and guests Drs Ip and Bakri for a podcast highlighting the challenges in care of patients with macular edema secondary to retinal vein occlusion (RVO). With the American Academy of Ophthalmology RVO Preferred Practice Pattern as a guide, the faculty consider the current approach to treatment using anti-vascular endothelial growth factor (VEGF) agents and factors that may suggest a need for more intensive, long-term treatment. The anti-VEGF agents have been standard of care for over a decade; however, many patients need frequent injections to be effective. The anti-VEGF agents faricimab and aflibercept 8 mg have shown noninferior efficacy and greater durability in pivotal clinical trials at reducing patient treatment burden.
When you are finished, please CLICK HERE to complete the posttest and evaluation.
TRANSCRIPT
REFERENCES